Project Grant R21AG104382
- The National Institute on Aging awarded the University of Virginia $583,815 on August 15, 2026, under the Aging Research program (CFDA 93.866) to support research into oligodendrocyte lineage dysfunction during aging and Alzheimer's disease. The project aims to understand how myelin loss—a pathology common to both aging and Alzheimer's disease—develops in the central nervous system and to identify therapeutic targets for cognitive impairment. The research focuses on oligodendrocyte precursor...
- The National Institute on Aging awarded the University of Virginia $131,166 on August 5, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of microglia-pericyte signaling in maintaining basal capillary tone in health and Alzheimer's disease. The research examines how microglia, brain-resident immune cells implicated in Alzheimer's disease pathology, regulate blood flow through capillaries by modulating pericyte function via cyclooxygenase-1 (COX1) and prostaglandin...
- The National Institute on Aging awarded New York University $642,063 under the Aging Research program (CFDA 93.866) on January 15, 2026, to investigate gabaergic circuit targets for modulating entorhinal cortex and hippocampal dynamics in Alzheimer's disease. The research examines vasoactive intestinal peptide and cholecystokinin inhibitory neuron microcircuits within hippocampal area CA1, with the hypothesis that modulating activity in these circuits can improve lateral entorhinal cortex–CA1...
- The National Institute on Aging awarded Virginia Commonwealth University $552,883 on January 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research on the selective vulnerability of cholinergic neurons in Alzheimer's disease. The award is a Project Grant with performance extending through November 30, 2030, at the Richmond, Virginia campus. The funded research investigates how soluble oligomeric amyloid-beta 42 (oAB42) drives selective degeneration of basal forebrain...
- The National Institute on Aging awarded Georgetown University $156,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate mitigation strategies for network dysfunction in Alzheimer's disease pathology. The project tests whether mild hyperpolarization can stabilize hippocampal network activity despite amyloid-beta-related impairment of excitatory amino acid transporters. The research quantifies sharp wave-ripples in ex vivo hippocampal slices from 5XFAD transgenic...
- The National Institute on Aging awarded the University of Virginia $2.877 million on July 1, 2026, under the Aging Research program (CFDA 93.866) to investigate microglia's role in neurovascular coupling and hypertensive cerebral small vessel disease. The project will test the hypothesis that microglial dysregulation of cerebral blood flow leads to hypertensive vascular dementia and endothelial rarefaction as common pathological events with Alzheimer's disease. Aim 1 will employ laser speckle...
- The National Institute on Aging awarded Duke University $1.597 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to support research on epitranscriptomic regulation of microglia in Alzheimer's disease. The research investigates how m6a methylation of adenosine residues in messenger RNA regulates microglial cell function and transitions between resting and activated states during Alzheimer's disease pathogenesis, with the goal of identifying novel...
- The National Institute on Aging awarded $427,625 to The Washington University on September 1, 2026, under the Aging Research program (CFDA 93.866) to probe cerebellar cortex computations in Alzheimer's disease. The work examines cerebellar nodulus and uvula function in two Alzheimer's disease mouse models—APP/PS1 and 3XTG-AD—at 3, 6, and 12 months of disease progression to assess how hallmarks of Alzheimer's disease contribute to cerebellar dysfunction. The project tests the hypothesis that...
- The National Institute on Aging awarded Emory University $643,613 on April 1, 2026, under the Aging Research program (CFDA 93.866) to discover glycosylation-based disease processes and identify glyco-biomarkers and targets for improving Alzheimer's disease diagnosis, prognosis, and intervention. The recipient will perform innovative research using an integrated platform of intact glycopeptide-based quantitative glycoproteomics and systems biology to elucidate brain glycoproteome alterations in...
- The National Institute on Aging, a component of the Department of Health and Human Services, awarded Massachusetts Institute of Technology $596,050 on September 15, 2026, under the Aging Research program (CFDA 93.866) to investigate fuzzy coat dynamics of post-translationally modified tau aggregation. The project examines structural properties of tau, a microtubule-associated protein whose aggregation hallmarks Alzheimer's disease and twenty other neurodegenerative diseases. The research tests...
The National Institute on Aging awarded the University of Virginia $433,417 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of hippocampal perineuronal net complexity in Alzheimer's disease-associated social memory dysfunction. The research examines how disruptions in perineuronal nets—specialized extracellular matrix structures surrounding neurons in the hippocampal CA2 region—contribute to social memory deficits in Alzheimer's disease. The project focuses on glycosaminoglycan chains and their sulfation isomers (C4S and C6S), which are key structural components of perineuronal nets but are not fully captured by current labeling techniques. The work will employ advanced methods to characterize these sulfation patterns and their relationship to social memory impairment in disease models, building on prior findings that restoring perineuronal net structure improves social memory function. The award is classified as a Project Grant, an assistance type supporting biomedical research directed toward understanding aging processes and age-related diseases. The period of performance runs from September 1, 2026, through August 31, 2028, with work performed in Charlottesville, Virginia.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $433.4k | 8/28/26 |